Tuesday, May 2, 2017

Advanced Cardiac Therapeutics Picks Up $45M

Santa Clara-based Advanced Cardiac Therapeutics (ACT), a medical device company which is developing an ablation catheter to treat cardiac arrhythmias including atrial fibrillation, said on Tuesday that it has raised $45M in an equity funding round. The funding was led by Ajax Health, and also included New Enterprise Associates and Questa Capital Management. The company says its catheter ablation systems uses temperature control, contact sensing, and high-resolution electrogram recording to treat atrial fibrillation through a minimally invasive approach. ACT's CEO is Duke Rohlen.